AKT

AKT
JianLi1989 · CC BY-SA 3.0 · source
Name	AKT
Uniprot	P31749

AKT

AKT is a family of serine/threonine kinases central to intracellular signaling networks downstream of receptor tyrosine kinases such as Epidermal growth factor receptor and Insulin receptor. AKT integrates inputs from pathways involving Phosphoinositide 3-kinase, Phosphatase and tensin homolog and mTOR, influencing cellular decisions studied in contexts ranging from Cancer staging and Diabetes mellitus to Cardiovascular disease and Neurodegeneration. Structural studies from groups at institutions like Cold Spring Harbor Laboratory, Harvard University, and Max Planck Society have detailed AKT conformations and interactions with regulatory proteins including PDK1 and 14-3-3 proteins.

Introduction

AKT denotes a conserved protein kinase family discovered through genetic screens in Drosophila melanogaster and oncogene studies in AKT8 virus from Harvey murine sarcoma virus research; it was subsequently linked to human oncogenesis by investigators at National Cancer Institute and Massachusetts Institute of Technology. Early biochemical work by laboratories at Stanford University and University of California, San Francisco established AKT as a principal effector of Phosphatidylinositol 3-kinase signaling, with downstream consequences described in papers published in journals such as Nature, Science, and Cell.

Structure and Isoforms

AKT proteins comprise an N-terminal pleckstrin homology (PH) domain, a central kinase domain, and a C-terminal regulatory tail characterized by a hydrophobic motif—features resolved by crystallography groups at European Molecular Biology Laboratory and Rutherford Appleton Laboratory. Mammals express three paralogs encoded by distinct genes: AKT1, AKT2, and AKT3, each mapped to human chromosomal loci characterized by geneticists at Wellcome Trust Sanger Institute and Broad Institute. Isoform-specific functions have been delineated through knockout mice generated at The Jackson Laboratory and transgenic models from Johns Hopkins University, revealing differential expression in tissues like liver, skeletal muscle, and brain reported by researchers at Columbia University and University College London.

Activation and Regulation

AKT activation requires recruitment to membranes via PH-domain binding to phosphatidylinositol (3,4,5)-trisphosphate produced by Phosphoinositide 3-kinase following stimulation of receptors such as Epidermal growth factor receptor, Insulin receptor and G protein-coupled receptor. Full activation is achieved after phosphorylation at activation loop sites by PDK1 and at hydrophobic motif residues by kinases including mTORC2 and DNA-PK, with deactivation mediated by phosphatases such as PTEN, PP2A, and PHLPP characterized in biochemical studies at Salk Institute and Institute of Cancer Research. Additional regulation occurs via ubiquitination enzymes studied at University of Cambridge and via interactions with scaffold proteins examined at Yale University.

Biological Functions

AKT controls cell survival, proliferation, metabolism, and growth through substrates identified in proteomic screens by consortia including Human Protein Atlas and teams at European Bioinformatics Institute. Phosphorylation targets include regulators of apoptosis like BAD and MDM2, cell-cycle controllers such as p21 (CDKN1A) and p27 (CDKN1B), metabolic enzymes including Glycogen synthase kinase 3 beta and AS160, and translational regulators via mTORC1 and S6 kinase. AKT signaling is pivotal in physiological processes investigated in clinical centers such as Mayo Clinic and Cleveland Clinic, including insulin-mediated glucose uptake studied in University of Oxford and synaptic plasticity explored at Salk Institute and Max Planck Institute for Brain Research.

Role in Disease

Aberrant AKT signaling is implicated in oncogenesis across tumor types catalogued by The Cancer Genome Atlas and studied at cancer centers like Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Activating mutations, amplifications, and pathway deregulation involving PIK3CA, PTEN, and AKT paralogs contribute to chemoresistance described in reports from European Society for Medical Oncology and American Society of Clinical Oncology. AKT dysregulation also features in metabolic disorders including Type 2 diabetes mellitus documented by World Health Organization data, cardiovascular pathology investigated at American Heart Association, and neurodegenerative diseases such as Alzheimer's disease explored by investigators at National Institutes of Health and Karolinska Institute.

Therapeutic Targeting

AKT and upstream components have been targeted by small molecules and biologics developed by pharmaceutical companies including Novartis, AstraZeneca, Roche, and Pfizer. ATP-competitive inhibitors, allosteric inhibitors, and isoform-selective compounds have progressed through clinical trials registered by ClinicalTrials.gov in oncology indications, with combination strategies pairing AKT inhibitors with agents targeting HER2, PARP inhibitors, and Immune checkpoint blockade tested at major cancer centers like MD Anderson Cancer Center. Resistance mechanisms involving compensatory activation of MAPK pathway and loss of PTEN have been reported in consortium studies from National Cancer Institute and industry partnerships.

Experimental Methods and Assays

AKT activity is assayed by phospho-specific antibodies recognizing phosphorylated residues developed by vendors referenced in protocols from Cold Spring Harbor Protocols, using techniques such as western blotting, immunohistochemistry used at Memorial Sloan Kettering Cancer Center, and mass spectrometry workflows optimized by Max Planck Institute for Biochemistry. Genetic perturbation employs CRISPR/Cas9 systems from groups at Broad Institute and RNA interference libraries from Harvard Medical School. Functional readouts include cell proliferation assays standardized by ATCC, metabolic flux analyses in facilities like Lawrence Berkeley National Laboratory, and in vivo models performed at vivaria such as Jackson Laboratory.

Category:Protein kinases